BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, today released an update from its Chairman, Richard Staelin, PhD, detailing sales growth, strategic initiatives, and progress in international arbitration. The company reported a small profit for calendar year 2025, driven by cost control measures including office relocation and staff reductions.
According to the update, BioElectronics has launched targeted advertising campaigns directed at medical professionals and healthcare providers to expand clinical awareness of RecoveryRx, its non-opioid pain management device. The company is also expanding consumer-focused social media advertising targeting Generation X consumers seeking drug-free solutions for chronic musculoskeletal pain.
In the professional market, BioElectronics continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The goal is to participate in a postoperative clinical study that may support qualification for reimbursement under the federal NO PAIN Act initiative. The company believes this represents a meaningful long-term opportunity and could support broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, BioElectronics is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor that allegedly breached contractual obligations. The company remains committed to protecting its intellectual property and shareholder interests.
BioElectronics also reported progress in its strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, with Electrome placing its initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform.
"This new endeavor represents an important operational milestone and provides another potential pathway to increase consumer awareness and access to our FDA-cleared, drug-free pain therapy products," Staelin said in the update. He emphasized that this relationship is part of a broader strategy including clinical market development, direct professional outreach, consumer education, and international opportunities.
The company remains focused on expanding revenues and markets while maintaining disciplined cost control. Despite challenges faced by emerging medical technology companies, BioElectronics is encouraged by growing interest in non-drug pain management solutions and believes it is well positioned within the evolving electroceutical and non-opioid pain management markets.
